Graham Parry
Stock Analyst at Citi
(2.09)
# 3,142
Out of 4,575 analysts
230
Total ratings
58.7%
Success rate
0.5%
Average return
Main Sectors:
Stocks Rated by Graham Parry
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| LON: GSK GSK plc | Initiated Coverage: Hold | 2,100p | 1,920p | +9.40% | 52 | Jul 24, 2026 | |
| SWX: NOVN Novartis AG | Maintained: Buy | CHF 132.00 → CHF 142.00 | CHF 126.90 | +11.90% | 52 | Jul 22, 2026 | |
| LON: 0QIU Novo Nordisk A/S | Maintained: Hold | kr 290.00 → kr 330.00 | kr 320.60 | +2.93% | 6 | Jul 20, 2026 | |
| LON: AZN AstraZeneca PLC | Maintained: Buy | 17,500p | 12,670p | +38.12% | 10 | Jul 10, 2026 | |
| SWX: ROP Roche Holding AG | Maintained: Buy | n/a | $355.10 | - | 5 | Mar 10, 2026 | |
| EPA: SAN Sanofi | Maintained: Hold | €85.00 → €80.00 | €76.03 | +5.22% | 40 | Feb 20, 2026 | |
| SNY Sanofi | Maintained: Buy | n/a | $43.35 | n/a | 17 | Jan 31, 2025 | |
| GSK GSK plc | Maintained: Sell | $19 | $51.35 | n/a | 23 | Dec 6, 2024 | |
| NVS Novartis AG | Rated: Hold | $118 → $130 | $155.01 | n/a | 17 | Sep 11, 2024 | |
| BME: GRF Grifols, S.A. | Initiated Coverage: Buy | €20.00 | €9.66 | n/a | 1 | Sep 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | 358p → 622p | 364p | n/a | 2 | Mar 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $88 | $129.31 | n/a | 1 | Mar 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $50 | $24.54 | n/a | 1 | Feb 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $34 | $54.70 | n/a | 1 | Sep 10, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Sell | n/a | $28.87 | n/a | 1 | Sep 10, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Sell | n/a | $5.46 | n/a | 1 | Oct 26, 2017 |
GSK plc
Jul 24, 2026
Initiated Coverage: Hold
Price Target: 2,100p
Current: 1,920p
Upside: +9.40%
Novartis AG
Jul 22, 2026
Maintained: Buy
Price Target: CHF 132.00 → CHF 142.00
Current: CHF 126.90
Upside: +11.90%
Novo Nordisk A/S
Jul 20, 2026
Maintained: Hold
Price Target: kr 290.00 → kr 330.00
Current: kr 320.60
Upside: +2.93%
AstraZeneca PLC
Jul 10, 2026
Maintained: Buy
Price Target: 17,500p
Current: 12,670p
Upside: +38.12%
Roche Holding AG
Mar 10, 2026
Maintained: Buy
Price Target: n/a
Current: $355.10
Upside: -
Sanofi
Feb 20, 2026
Maintained: Hold
Price Target: €85.00 → €80.00
Current: €76.03
Upside: +5.22%
Sanofi
Jan 31, 2025
Maintained: Buy
Price Target: n/a
Current: $43.35
Upside: n/a
GSK plc
Dec 6, 2024
Maintained: Sell
Price Target: $19
Current: $51.35
Upside: n/a
Novartis AG
Sep 11, 2024
Rated: Hold
Price Target: $118 → $130
Current: $155.01
Upside: n/a
Grifols, S.A.
Sep 12, 2023
Initiated Coverage: Buy
Price Target: €20.00
Current: €9.66
Upside: n/a
Mar 7, 2023
Reiterated: Buy
Price Target: 358p → 622p
Current: 364p
Upside: n/a
Mar 3, 2023
Maintained: Hold
Price Target: $88
Current: $129.31
Upside: n/a
Feb 28, 2023
Maintained: Hold
Price Target: $50
Current: $24.54
Upside: n/a
Sep 10, 2018
Downgraded: Hold
Price Target: $34
Current: $54.70
Upside: n/a
Sep 10, 2018
Downgraded: Sell
Price Target: n/a
Current: $28.87
Upside: n/a
Oct 26, 2017
Downgraded: Sell
Price Target: n/a
Current: $5.46
Upside: n/a